Radiopharm Theranostics RADX
NASDAQ RADX
$0.88 -0.07 (-7.70%)
At close: Nov 9, 2026 · 4:00 PM EST

Radiopharm Theranostics (RADX) Net Income Attributable to Noncontrolling Interests (2023)

Updated

Radiopharm Theranostics (RADX) reported Income from Non-Controlling Interests of -$12,234 for FY2026 (year ended Jun 30, 2026), compared with -$1.64 million in FY2025.

Analysis

Radiopharm Theranostics (RADX) Net Income Attributable to Noncontrolling Interests (2023) Analysis & Trends

Dating back to FY2023, Radiopharm Theranostics' Income from Non-Controlling Interests record includes 4 fiscal years.

  • According to Business Quant data, Income from Non-Controlling Interests came in at -$1.64 million in FY2025, -$1.96 million in FY2024 and -$162,529 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn -
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn -
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn 2.00 Mn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn -
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn -
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn 10.00 Mn
10 Radiopharm Theranostics 2.70 Bn 2.62 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 -162,529.00
API Access

Radiopharm Theranostics Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=RADX&period=max&api_key=YOUR_API_KEY